title: [Etanercept: does it constitute a risk factor for development of cerebral venous thrombosis?].
authors.affiliation: Hospitales Universitarios Virgen del Rocio, 41013 Sevilla, Espana.
authors.forename: María
authors.initials: M
authors.lastname: Usero-Ruiz
authors.forename: María
authors.initials: M
authors.lastname: Díaz-Sánchez
authors.forename: Francisco
authors.initials: F
authors.lastname: Moniche-Álvarez
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood; D016736:Antiphospholipid Syndrome / Q000150:complications*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D001323:Autoantibodies / Q000097:blood; D003244:Consciousness Disorders / Q000209:etiology; D004359:Drug Therapy, Combination; D004630:Emergencies; D000068800:Etanercept; D005260:Female; D006801:Humans; D006849:Hydrocephalus / Q000209:etiology; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D010291:Paresis / Q000209:etiology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012851:Sinus Thrombosis, Intracranial / Q000139:chemically induced* / Q000209:etiology / Q000276:immunology; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000209:etiology; D014057:Tomography, X-Ray Computed; D053482:beta 2-Glycoprotein I / Q000276:immunology
chemical_list: D000305:Adrenal Cortex Hormones; D017153:Antibodies, Anticardiolipin; D018501:Antirheumatic Agents; D001323:Autoantibodies; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D053482:beta 2-Glycoprotein I; D000068800:Etanercept; D008727:Methotrexate